Body growth in early diagnosed vesicoureteric reflux.
Body growth was studied in 32 subjects with vesicoureteric reflux (VUR), diagnosed following the prenatal finding of urinary tract dilatation, who had normal renal filtration function and who received antibacterial prophylaxis by the first few days of life. They were followed for 1-5 years (mean 2.3 years). Most had persistent VUR during the 1st year of life. Body growth performance was compared with that of 94 subjects with VUR diagnosed and treated by us after the neonatal period. During the follow-up period, none of the patients with prenatally detected VUR had a height Z score below -2, nor a weight-for-height index below 90%, and 1 had variations in height Z score >/=1. The difference in the percentage of patients with prenatally detected VUR (1/32) and those with VUR diagnosed and treated after the neonatal period (20/94) who had variations in height Z score >/=1 was significant (P=0.035). Patients with prenatally detected VUR and normal renal filtration function, given antibacterial prophylaxis by the first few days of life, have normal body growth, although VUR still persists.
Polito
C
C
Department of Pediatrics, 3rd Pediatric Clinic, Second University of Naples, Naples, Italy.
La Manna
A
A
Mansi
L
L
Rambaldi
P F
PF
Papale
M R
MR
Marte
A
A
Di Toro
R
R
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D005260:Female; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D007769:Lactams; D008297:Male; D011296:Prenatal Diagnosis; D012189:Retrospective Studies; D013997:Time Factors; D016216:Ultrasonography, Prenatal; D014552:Urinary Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D014718:Vesico-Ureteral Reflux / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*
D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D007769:Lactams